<SEC-DOCUMENT>0001376339-22-000060.txt : 20220503
<SEC-HEADER>0001376339-22-000060.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503163704
ACCESSION NUMBER:		0001376339-22-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220503
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		22887622

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mdxg-20220503.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:0b91f1d9-4617-469a-8aa9-380c4b267417,g:79bf9f41-a05a-4c6f-899a-c4309277e51b,d:697630caadf548b1a6f1434ff833b1c6--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdxg-20220503</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl80L2ZyYWc6MWNhNThlMGNkYWQyNDZmNmFlMTUyYjdmMDZlYWZhNzcvdGFibGU6NTY2ODhiODM3ZjZmNDlkNDhiZmI5NzEzZjQyMzJmM2YvdGFibGVyYW5nZTo1NjY4OGI4MzdmNmY0OWQ0OGJmYjk3MTNmNDIzMmYzZl8yLTEtMS0xLTc3NDIw_0a755b4b-cb64-4434-a05b-7959b8f260c0">0001376339</ix:nonNumeric><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl80L2ZyYWc6MWNhNThlMGNkYWQyNDZmNmFlMTUyYjdmMDZlYWZhNzcvdGFibGU6NTY2ODhiODM3ZjZmNDlkNDhiZmI5NzEzZjQyMzJmM2YvdGFibGVyYW5nZTo1NjY4OGI4MzdmNmY0OWQ0OGJmYjk3MTNmNDIzMmYzZl80LTEtMS0xLTc3NDIw_1bc7fe50-b88d-46aa-93d3-c92c5eb0de75">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdxg-20220503.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i989923ec8f974009805151eba4d91949_D20220503-20220503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i697630caadf548b1a6f1434ff833b1c6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg0_8ce95c2a-b14e-4d3c-9285-363a3b9370a6">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl8yNjY_f48689a5-0dd2-4c61-b448-5fb70793811b">May 3, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg5_ae608f3a-b091-43f4-b30c-fd07402c789f">MIMEDX GROUP, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTAtMS0xLTc3NDIw_ae6530f7-35d4-4b76-ab4d-e9e342aab0db">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTItMS0xLTc3NDIw_7923f93d-bbee-4775-9da8-3ffe76dc68dd">001-35887</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTQtMS0xLTc3NDIw_36eb94eb-e917-4ae0-b85c-6e8f2c86dcb9">26-2792552</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTkw_025c131a-5c10-4447-8447-26f9ddd048a8">1775 West Oak Commons Ct., NE</ix:nonNumeric>, <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg1_9340804d-f6dd-4db1-be41-cc9d6f9275db">Marietta</ix:nonNumeric> <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTkx_16925e31-1f02-4ec9-bfc6-27ed63549eee">GA</ix:nonNumeric> <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg2_3e2fbf16-087b-4141-aeee-e189418cca4b">30062</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg3_eb1c3b23-b6b1-483e-ae33-d749a898ad66">770</ix:nonNumeric>) <ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg4_e357642c-7036-44bc-b6ed-04cf304b41be">651-9100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8wLTAtMS0xLTc3NDIw_189cb5bb-4bdc-4a9e-88c6-d580c2c9aa00">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8xLTAtMS0xLTc3NDIw_c80ecec4-7151-44f8-86bf-a1a53d79ca37">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8yLTAtMS0xLTc3NDIw_9f156762-652b-44f5-a1c5-224a0aa0b0ce">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8zLTAtMS0xLTc3NDIw_40a15f88-88a5-4655-b6c7-a24e85cad22b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:27.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTAtMS0xLTc3NDIw_78732303-b55c-4aa2-95d3-a87f6572693c">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTItMS0xLTc3NDIw_972f7133-ca8c-409e-9284-6d5f7f87882a">MDXG</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTQtMS0xLTc3NDIw_26f680cd-9086-4570-84db-a26384bc0419">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTky_93d9ea11-b403-4c60-9f20-2eda31d53fd9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Important Cautionary Statement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) our 2022 financial outlook and expectations for future financial results, including net sales and levels of selling, general, and administrative expense; (iii) our expectations regarding the timing of clinical programs and trials; (iv) our expectations regarding the timing of new product launches; and (v) the effectiveness of amniotic tissue as a therapy for any particular indication or condition. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," &#8220;goal,&#8221; &#8220;outlook,&#8221; "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; (ii) the status, timing, results and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with Current Good Manufacturing Practices (CGMP) and appropriate chemistry and manufacturing controls; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements; (iv) our access to hospitals and health care provider facilities could be restricted as a result of the ongoing COVID-19 pandemic or other factors; (v) the results of scientific research are uncertain and may have little or no value; (vi) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (vii) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (viii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2022, MiMedx Group, Inc. (the &#8220;Company&#8221;), issued a press release (the &#8220;Earnings Press Release&#8221;) announcing  its results for the first quarter ended March 31, 2022. A copy of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing information is furnished pursuant to Item 2.02, &#8220;Results of Operations and Financial Condition.&#8221; Consequently, it is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K. All information in the Earnings Press Release speaks as of the date thereof and the Company does not assume any obligation to update said information in the future. In addition, the Company disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220503ex991q12022earnin.htm">Earnings Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220503ex991q12022earnin.htm">Ma</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220503ex991q12022earnin.htm">y 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220503ex991q12022earnin.htm">, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20220503ex991q12022earnin.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MIMEDX GROUP, INC.</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20220503ex991q12022earnin.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib53473c1c98d44eab2d986c37e465915_1"></div><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:140%">EXHIBIT 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">MIMEDX Announces First Quarter 2022 Operating and Financial Results</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:145%">Management to Host Conference Call on May 4, 2022, at 8&#58;30 AM ET </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">MARIETTA, Ga., May&#160;3, 2022</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%"> -- MiMedx Group, Inc. (Nasdaq&#58; MDXG) (&#8220;MIMEDX&#8221; or the &#8220;Company&#8221;), a transformational placental biologics company, today announced the filing of its first quarter 2022 Form 10-Q for the period ended March&#160;31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Timothy R. Wright, MIMEDX Chief Executive Officer, commented, &#8220;For the third consecutive quarter, the team delivered double-digit growth in our Advanced Wound Care products, achieving a 13% increase year-over-year. The fundamentals of our growth strategy are driving strong performance, and we are executing against our stated objectives. We have re-designed our training program for our sales professionals to improve revenue generation through more consistent, effective and aligned messaging that communicates the clinical and economic value of MIMEDX products. We also are gaining traction in the under-penetrated Surgical Recovery market, due in part to our recent publication involving clinical effectiveness in Mohs surgery, and escalating the adoption of our PURION&#174; processed tissue technologies where conventional treatments have safety or efficacy limitations and patients are seeking a better outcome.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Mr. Wright continued, &#8220;Our Commercial, Research and Product Development teams are collaborating and executing, and we are making significant progress towards our milestones. Leading up to the launch of EPIFIX&#174; in Japan, we have gained the support of prominent medical societies and identified clinical sites for initial product evaluations. In preparation for the launches of our AMNIOEFFECT&#8482; and Placental Collagen Matrix platform technologies in the U.S. market, we have completed a number of market development focus groups with industry thought-leaders and key stakeholders, and are advancing research initiatives that enable our commercial strategy and expand the scientific foundation behind our placental biologics portfolios.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">&#8220;With regard to our late-stage clinical pipeline, we view our micronized dehydrated Human Amnion Chorion Membrane (mdHACM) platform as an outstanding opportunity, and we are taking critical steps to accelerate the initiation of trial enrollment in our planned Knee Osteoarthritis (KOA) clinical trial program. Consistent with industry best practices, we are lining up industry-leading clinical and scientific resources to augment our own efforts, along with world-class experts in the field of osteoarthritis. It is imperative we fast-track these research initiatives to build on the promising data derived from our Phase 2B KOA study and further educate the market on the potential impact of mdHACM on the underlying </font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">disease process. If approved, we believe there is tremendous revenue generation potential in these programs, and we are working tirelessly to accelerate our path to serving these patients suffering from a void in safe and effective treatment options.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">MIMEDX is determined to drive meaningful, long-term value across its core Wound Care and Surgical Recovery business, as well as its late-stage musculoskeletal pipeline. Effective April 2022, MIMEDX created two defined, cohesive internal business units within the Company&#58; one focused on Wound Care and Surgical Recovery markets, its existing product portfolio, and near-term innovation, led by Dr. Rohit Kashyap (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:162%">President, Wound Care &#38; Surgical)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">&#59; and the other, led by Dr. Robert Stein (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:162%">President, Regenerative Medicine &#38; Biologics Innovation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">), focused solely on Regenerative Medicine technologies, specifically progressing its placental biologics platform towards registration as a U.S. Food &#38; Drug Administration (FDA) approved biological drug.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Mr. Wright added, &#8220;This organizational alignment is designed to enable dedicated key contributors to work in collaboration, functioning in a way that streamlines operations and positions necessary resources, infrastructure and expertise critical to innovation and value creation. The senior leadership team we have assembled at MIMEDX is talented, experienced and well-equipped to accomplish the strategic initiatives we have outlined, and I am confident this organizational structure best potentiates our collective ability to innovate, execute and achieve the next phase of growth for MIMEDX.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Recent Operating and Financial Highlights&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Reported first quarter net sales of $58.9 million, down less than 2% from the prior year quarter despite the loss of revenue from Section 351 products (as defined below). Net sales of the Company's continuing portfolio of tissue and cord products increased 13% versus the same period last year.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Announced the publication of a peer-reviewed study in the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:162%">Journal of Wound Care </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">that demonstrated the cost-effectiveness of EPIFIX compared with standard of care in treating lower extremity diabetic foot ulcers, noting a significant reduction in major amputations and hospital utilization.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Presented cost-effectiveness data for EPIFIX at the Symposium on Advanced Wound Care (SAWC) Spring Meeting&#58; &#34;Reducing Costs While Preserving Lives &#38; Limbs in Medicare Patients - Cost-Effectiveness of Dehydrated Human Amnion Chorion Membrane Allografts in the Treatment of Lower Extremity Diabetic Ulcers.&#34;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Presented scientific poster at SAWC Spring Meeting titled &#34;PURION processed Placental Biologics Retain Critical Activity for Healing Fibrotic Wounds.&#34;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Key First Quarter 2022 Financial Metrics</font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Net sales of $58.9 million for first quarter 2022, compared to $60.0 million for the prior year period</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Net loss of $10.5 million for first quarter 2022, compared to a net loss of $8.4 million for the prior year period</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:162%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;padding-left:12.53pt">Adjusted EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:162%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%"> of $(1.7)&#160;million for first quarter 2022, compared to $5.0 million for the prior year period</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:77.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.987%"><tr><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;58,894</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;59,967</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,489)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,382)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,268)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,452)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Adjusted EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,718)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.11)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.09)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.11)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.09)</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%;padding-left:11.94pt">EBITDA and Adjusted EBITDA are non-GAAP financial measures. See &#8220;Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA&#8221; for a reconciliation of EBITDA and Adjusted EBITDA to Net loss, located in &#8220;Selected Unaudited Financial Information&#8221; of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">MIMEDX reported net sales for the three months ended March 31, 2022, of $58.9 million, compared to $60.0 million for the three months ended March 31, 2021, a decrease of 1.8%. Net sales in the first quarter of 2022 include $0.4 million of Section 351 products, compared to $8.1 million in the first quarter of 2021. This reflects the May 31, 2021 end of the FDA's period of enforcement discretion, after which the Company was no longer able to market Section 351 products in the United States. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">First quarter net sales of the continuing portfolio of tissue and cord products increased 13% compared to the same period last year, reflecting the impact of strategic commercial initiatives, including growth in the Surgical Recovery market. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">MIMEDX has two primary classes of products&#58; (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products, and (2) Section 351 products, consisting of the Company&#8217;s micronized and particulate products. Advanced Wound Care is further disaggregated between the Company&#8217;s Tissue&#47;Other and Cord products. A summary of the Company's revenue, including revenue derived from its Section 351 products, is included in the table below (amounts in thousands)&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Wound Care</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue&#47;Other</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;52,852</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;46,569</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;6,283</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cord</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Advanced Wound Care</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,449</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,529</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,920</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Section 351</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,140</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,763)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.4)&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Other</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.2)&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;58,894</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;59,967</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(1,073)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)&#160;&#160;&#160;&#160;%</font></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%;padding-left:11.94pt">In connection with new guidance provided by the FDA in November 2017, the FDA chose to exercise enforcement discretion with respect to investigational new drug applications and pre-market approval requirements for certain products regulated as Human Cells, Tissues and Cellular and Tissue-Based Products (HCT&#47;Ps) through May 31, 2021 (referred to as the period of Enforcement Discretion).</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%;padding-left:11.94pt">&#8220;Other&#8221; represents revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Gross profit margin for the three months ended March 31, 2022, was 83.1% compared to 83.9% for the three months ended March 31, 2021. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Selling, general and administrative expenses for the three months ended March 31, 2022, were $49.6 million, compared to $45.4 million for the three months ended March 31, 2021. The increase in selling, general and administrative expenses reflects increases in personnel costs, sales commissions and travel expenses. Increases in personnel costs and sales commissions were the result of sales force realignment and expansion&#59; additionally, the Company's focus on sales of products into areas of Surgical Recovery results in a proportional increase in sales through sales agents. The increase in travel expenses reflects the removal of travel restrictions that the Company had in place during the first quarter of 2021 due to the Covid-19 pandemic.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">After the end of the FDA's period of Enforcement Discretion, MIMEDX made the strategic decision to maintain its staffing levels, including for its sales force, in support of its commercial growth objectives. As a result, the level of selling, general and administrative expenses as a percentage of net sales is higher in the first quarter of 2022 compared to the prior year quarter and to its historical trends. In addition, due primarily to the annual reset of insurance deductibles at the beginning of each calendar year, net sales in the first quarter are typically lower than in other quarters within a single year. The Company therefore expects the level of selling, general and administrative expenses as a percentage of net sales to decline over the remainder of 2022.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Research and development expenses were $6.0 million for the three months ended March 31, 2022, compared to $4.3 million for the three months ended March 31, 2021. The increase reflects higher personnel costs, driven by increases in headcount to support clinical research efforts connected to the Company's commercial and late-stage pipelines.</font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Investigation, restatement and related expenses for the three months ended March 31, 2022, were $2.6 million compared to $7.2 million for the three months ended March 31, 2021. The decrease was primarily the result of a decline in legal fees advanced on behalf of certain former officers and directors of the Company. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Net loss for the three months ended March 31, 2022, was $10.5 million compared to a net loss of $8.4 million for the three months ended March 31, 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">As of March&#160;31, 2022, the Company had $75.7 million of cash and cash equivalents, compared to $87.1 million as of December 31, 2021. The decrease during the three months ended March&#160;31, 2022 reflects payments of accrued compensation, which included the payment of annual incentives, and the payment of payroll taxes, some of which had been deferred under the Coronavirus Aid, Relief, and Economic Security Act.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Outlook for 2022</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">The Company maintained its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022, as it plans to launch EPIFIX in Japan, as well as two new products in the U.S., AMNIOEFFECT and its Placental Collagen Matrix product, later this year.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Conference Call and Webcast</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">MIMEDX will host a conference call and webcast to review its first quarter 2022 results on Wednesday, May 4, 2022, beginning at 8&#58;30 a.m., Eastern Time. The call can be accessed using the following information&#58;</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Webcast&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Click here</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">U.S. Investors&#58; 877-407-6184</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">International Investors&#58; 201-389-0877</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Conference ID&#58; 13728444</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">A replay of the webcast will be available for approximately 30 days on the Company&#8217;s website at www.mimedx.com following the conclusion of the event.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Important Cautionary Statement </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">This press release includes forward-looking statements. Statements regarding&#58; (i) future sales or sales growth&#59; (ii) our 2022 financial outlook and expectations for future financial results, including net sales and levels of selling, general, and administrative expense&#59; (iii) our expectations regarding the timing of </font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">clinical programs and trials&#59; (iv) our expectations regarding the timing of new product launches&#59; and (v) the effectiveness of amniotic tissue as a therapy for any particular indication or condition. Additional forward-looking statements may be identified by words such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;plan,&#34; &#8220;goal,&#8221; &#8220;outlook,&#8221; &#34;potential,&#34; &#34;will,&#34; &#34;preliminary,&#34; and similar expressions, and are based on management's current beliefs and expectations. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include&#58; (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors&#59; (ii) the status, timing, results and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with Current Good Manufacturing Practices (CGMP) and appropriate chemistry and manufacturing controls&#59; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements&#59; (iv) our access to hospitals and health care provider facilities could be restricted as a result of the ongoing COVID-19 pandemic or other factors&#59; (v) the results of scientific research are uncertain and may have little or no value&#59; (vi) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship&#59; (vii) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies&#59; and (viii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Important Additional Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">The Company, its directors, director nominees and certain of its executive officers are participants in the solicitation of proxies from the Company&#8217;s shareholders in connection with the 2022 annual meeting of shareholders (the &#8220;2022 Annual Meeting&#8221;). The Company has filed a definitive proxy statement and a WHITE proxy card with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with any such solicitation of proxies from the Company&#8217;s shareholders. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. The Company&#8217;s definitive proxy statement for the 2022 Annual Meeting </font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company&#8217;s directors, director nominees and executive officers in the matters to be acted upon at the 2022 Annual Meeting. Information regarding subsequent changes to their holdings of the Company&#8217;s securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company&#8217;s website at www.mimedx.com or through the SEC&#8217;s website at www.sec.gov. Information can also be found in the Company&#8217;s other SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021. Shareholders are able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC&#8217;s website at www.sec.gov. Copies are also available at no charge on the Company&#8217;s website at www.mimedx.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">About MIMEDX</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION&#174; process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;text-decoration:underline">www.mimedx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Contacts&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Investors&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Jack Howarth</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Investor Relations</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">404.360.5681</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;text-decoration:underline">jhowarth&#64;mimedx.com</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Media&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Hilary Dixon </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">Corporate &#38; Strategic Communications </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">404.323.4779</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%;text-decoration:underline">hdixon&#64;mimedx.com </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%"> </font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:140%">Selected Unaudited Financial Information</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">March 31,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:145%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;75,676</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;87,083</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,674</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,353</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,170</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,389</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,907</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,523</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,759</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,165</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,696</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,976</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,976</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;174,443</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;187,929</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;8,120</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;7,385</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,102</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,595</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,591</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,357</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,239</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,127</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,383</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,353</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,494</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,494</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' deficit (equity)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,434)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit (equity)</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;174,443</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;187,929</font></td></tr></table></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:58.87pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"></td><td style="width:66.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Operations</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;58,894</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;59,967</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,641</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,958</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,326</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,570</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,404</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,339</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigation, restatement and related</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,196</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,300)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,852)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,126)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,472)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax provision</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,426)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,324)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(10,489)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(8,382)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common shareholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(12,075)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(9,850)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.11)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.09)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.11)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(0.09)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,615,839</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,401,383</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,615,839</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,401,383</font></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(10,489)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(8,382)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flows used in operating activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of asset retirement obligation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on fixed asset disposal</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash resulting from changes in&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(936)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,494)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,314)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows used in operating activities</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,223)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,679)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash&#160;flows from investing activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,941)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent application costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equipment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments from note receivable</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows used in investing activities</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock repurchased for tax withholdings on vesting of restricted stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,191)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,216)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on finance lease</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flows used in financing activities</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,036)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,308)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,407)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,083</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,812</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;75,676</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;84,746</font></td></tr></table></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">In addition to our GAAP results, we provide certain non-GAAP metrics including Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;) and Adjusted EBITDA. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements. Company management uses these Non-GAAP measurements as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies. </font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">EBITDA is intended to provide a measure of the Company&#8217;s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net loss excluding&#58; (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, net, and (iv) income tax provision. Adjusted EBITDA is intended to provide a normalized view of EBITDA and our broader business operations that we expect to experience on an ongoing basis by removing certain non-cash items and items that may be irregular, one-time, or non-recurring from EBITDA. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted EBITDA consists of GAAP net loss excluding&#58; (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, (iv) income tax provision, (v) costs incurred in connection with Audit Committee Investigation and Restatement, and (vi) share-based compensation.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:154%">A reconciliation of GAAP net loss to EBITDA and Adjusted EBITDA appears in the table below (in thousands)&#58;</font></div><div style="padding-left:48.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.326%"><tr><td style="width:1.0%"></td><td style="width:57.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(10,489)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(8,382)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17.8)&#160;&#160;&#160;&#160;%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14.0)&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision expense, net</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,268)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,452)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EBITDA margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14.0)&#160;&#160;&#160;&#160;%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9.1)&#160;&#160;&#160;&#160;%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Non-GAAP Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred in connection with Audit Committee Investigation and Restatement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,196</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBTIDA</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;(1,718)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;4,988</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.9)&#160;&#160;&#160;&#160;%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;%</font></td></tr></table></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mdxg-20220503.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0b91f1d9-4617-469a-8aa9-380c4b267417,g:79bf9f41-a05a-4c6f-899a-c4309277e51b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdxg="http://mimedx.com/20220503" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://mimedx.com/20220503">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20220503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://mimedx.com/role/CoverPageDocument">
        <link:definition>0001001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mdxg-20220503_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0b91f1d9-4617-469a-8aa9-380c4b267417,g:79bf9f41-a05a-4c6f-899a-c4309277e51b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_ff7dc2a7-6403-4167-a627-4608a875bc75_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e7806c6d-b96c-4a62-9123-da21e6c6c314_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_68ce639f-3bb7-413f-8b8a-893fc6cae6d4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9b6b3f25-161f-4fb5-b7fe-986c1e64d818_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5def5f3c-d1a0-4f6f-8175-574552c830fd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_25e70efa-cd31-4f05-b1f1-10f5b00188d2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_56cbbf90-df07-4eca-a0f3-4e7b67fcb96a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_67734a60-c672-4288-b87d-fbf46e40ba60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a294f525-77eb-41a7-ab87-ecfd18d2f4c0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b7e28101-05ee-40bd-a459-9ee382a3d700_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7c6a09e8-e56e-460b-9348-f7115ed399d0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7141680b-a86d-424e-ba4e-e38232994013_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_583dc286-3ee0-4237-b236-4ba775597420_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fa1aeef9-05b2-48d1-b693-863748a53134_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3e6963b7-f2dc-413a-99f7-675e47c1d30f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_35012432-b97c-4fee-a82b-6453d1a95bf4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_632b8157-0c63-4d93-8260-7afeed4416dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_81ef5c1f-d338-4df3-9e69-c8cd5ddabbd8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f7b917cc-7a16-4fc5-93ca-18cbc5c7eb4e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3febd775-e35b-4478-808e-058d4e7ef13d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4d13a754-fd3b-49cd-9526-e099f7ab895d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_269d79de-363c-4b11-83a4-40dbe79903cd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ab776be5-724d-44c1-9533-c199081f83d6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mdxg-20220503_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0b91f1d9-4617-469a-8aa9-380c4b267417,g:79bf9f41-a05a-4c6f-899a-c4309277e51b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mimedx.com/role/CoverPageDocument" xlink:type="simple" xlink:href="mdxg-20220503.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_38334b22-ae3d-4f94-a3f0-6babd7fd0bbe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_DocumentType_38334b22-ae3d-4f94-a3f0-6babd7fd0bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4bd3ee2f-462b-45ae-a63b-8545b5052ffe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_DocumentPeriodEndDate_4bd3ee2f-462b-45ae-a63b-8545b5052ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7a5f0c41-9ff2-4b9e-abbc-dfbe5c41bc99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityRegistrantName_7a5f0c41-9ff2-4b9e-abbc-dfbe5c41bc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b762c98b-6ad3-44e6-b6c1-e6d898aae686" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b762c98b-6ad3-44e6-b6c1-e6d898aae686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1b709515-fcf5-43e7-9445-e7dce454931d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityFileNumber_1b709515-fcf5-43e7-9445-e7dce454931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a68b733-069f-457f-a64f-ca1b83e9704e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a68b733-069f-457f-a64f-ca1b83e9704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_36449e78-79f8-48e7-bb65-1613e2a73ebf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityAddressAddressLine1_36449e78-79f8-48e7-bb65-1613e2a73ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f4789aac-922a-43c1-b91a-ae1d0797c75c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityAddressCityOrTown_f4789aac-922a-43c1-b91a-ae1d0797c75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_645aa558-564a-4988-a44c-08d9072442fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityAddressStateOrProvince_645aa558-564a-4988-a44c-08d9072442fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0410175c-2cbf-43d6-9a37-445106b52f0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityAddressPostalZipCode_0410175c-2cbf-43d6-9a37-445106b52f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d17b938d-0fc9-4707-b2bc-56dca50c0add" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_CityAreaCode_d17b938d-0fc9-4707-b2bc-56dca50c0add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fb488c32-b8d0-43c0-8188-bd10e531f21f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_LocalPhoneNumber_fb488c32-b8d0-43c0-8188-bd10e531f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_08b684d8-3603-4c28-a880-d23a636b9508" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_WrittenCommunications_08b684d8-3603-4c28-a880-d23a636b9508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c2130333-8077-451c-89e9-2f05ce95fb8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_SolicitingMaterial_c2130333-8077-451c-89e9-2f05ce95fb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b9d9b3f7-e759-4cfd-b755-ed5df9ffbd31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_PreCommencementTenderOffer_b9d9b3f7-e759-4cfd-b755-ed5df9ffbd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_541debd2-5d01-425c-9066-91eab262fcfd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_541debd2-5d01-425c-9066-91eab262fcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_432042b2-f2e8-4120-aa07-761a1ee5971a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_Security12bTitle_432042b2-f2e8-4120-aa07-761a1ee5971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_92130c13-645e-40f7-b3ac-6bd54f2a8248" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_TradingSymbol_92130c13-645e-40f7-b3ac-6bd54f2a8248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9a3a7509-269e-4da5-9a0f-42a7d9b102b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_SecurityExchangeName_9a3a7509-269e-4da5-9a0f-42a7d9b102b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d9500541-7a8b-48e5-b2e1-3e5a24c2bcc1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityEmergingGrowthCompany_d9500541-7a8b-48e5-b2e1-3e5a24c2bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_13d4dafe-572d-45fb-a383-bfaa7c8909f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_EntityCentralIndexKey_13d4dafe-572d-45fb-a383-bfaa7c8909f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7ea059fe-4cac-4902-9698-5ab6960953c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dac7e490-1a94-4245-bde5-89addb4e8008" xlink:to="loc_dei_AmendmentFlag_7ea059fe-4cac-4902-9698-5ab6960953c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140201487415096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>May 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MIMEDX GROUP, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2792552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1775 West Oak Commons Ct., NE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marietta<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-9100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDXG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001376339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>mdxg-20220503_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdxg-20220503.xsd" xlink:type="simple"/>
    <context id="i989923ec8f974009805151eba4d91949_D20220503-20220503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl80L2ZyYWc6MWNhNThlMGNkYWQyNDZmNmFlMTUyYjdmMDZlYWZhNzcvdGFibGU6NTY2ODhiODM3ZjZmNDlkNDhiZmI5NzEzZjQyMzJmM2YvdGFibGVyYW5nZTo1NjY4OGI4MzdmNmY0OWQ0OGJmYjk3MTNmNDIzMmYzZl8yLTEtMS0xLTc3NDIw_0a755b4b-cb64-4434-a05b-7959b8f260c0">0001376339</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl80L2ZyYWc6MWNhNThlMGNkYWQyNDZmNmFlMTUyYjdmMDZlYWZhNzcvdGFibGU6NTY2ODhiODM3ZjZmNDlkNDhiZmI5NzEzZjQyMzJmM2YvdGFibGVyYW5nZTo1NjY4OGI4MzdmNmY0OWQ0OGJmYjk3MTNmNDIzMmYzZl80LTEtMS0xLTc3NDIw_1bc7fe50-b88d-46aa-93d3-c92c5eb0de75">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg0_8ce95c2a-b14e-4d3c-9285-363a3b9370a6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl8yNjY_f48689a5-0dd2-4c61-b448-5fb70793811b">2022-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg5_ae608f3a-b091-43f4-b30c-fd07402c789f">MIMEDX GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTAtMS0xLTc3NDIw_ae6530f7-35d4-4b76-ab4d-e9e342aab0db">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTItMS0xLTc3NDIw_7923f93d-bbee-4775-9da8-3ffe76dc68dd">001-35887</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6ZGU1MGFlNzIxYWEwNDI4YzgzMzYzN2I1NGI5OTgxYzEvdGFibGVyYW5nZTpkZTUwYWU3MjFhYTA0MjhjODMzNjM3YjU0Yjk5ODFjMV8wLTQtMS0xLTc3NDIw_36eb94eb-e917-4ae0-b85c-6e8f2c86dcb9">26-2792552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTkw_025c131a-5c10-4447-8447-26f9ddd048a8">1775 West Oak Commons Ct., NE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg1_9340804d-f6dd-4db1-be41-cc9d6f9275db">Marietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTkx_16925e31-1f02-4ec9-bfc6-27ed63549eee">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg2_3e2fbf16-087b-4141-aeee-e189418cca4b">30062</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg3_eb1c3b23-b6b1-483e-ae33-d749a898ad66">770</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTg4_e357642c-7036-44bc-b6ed-04cf304b41be">651-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8wLTAtMS0xLTc3NDIw_189cb5bb-4bdc-4a9e-88c6-d580c2c9aa00">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8xLTAtMS0xLTc3NDIw_c80ecec4-7151-44f8-86bf-a1a53d79ca37">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8yLTAtMS0xLTc3NDIw_9f156762-652b-44f5-a1c5-224a0aa0b0ce">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MWE2ZDRmNDljNTM5NDI5YmJlNGQ2ZmQyNDI3MjFiNTgvdGFibGVyYW5nZToxYTZkNGY0OWM1Mzk0MjliYmU0ZDZmZDI0MjcyMWI1OF8zLTAtMS0xLTc3NDIw_40a15f88-88a5-4655-b6c7-a24e85cad22b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTAtMS0xLTc3NDIw_78732303-b55c-4aa2-95d3-a87f6572693c">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTItMS0xLTc3NDIw_972f7133-ca8c-409e-9284-6d5f7f87882a">MDXG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGFibGU6MGExZjhkNWJmNDhkNGY2ZWJmMDQxZDBkMTc0NzBkMjMvdGFibGVyYW5nZTowYTFmOGQ1YmY0OGQ0ZjZlYmYwNDFkMGQxNzQ3MGQyM18xLTQtMS0xLTc3NDIw_26f680cd-9086-4570-84db-a26384bc0419">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i989923ec8f974009805151eba4d91949_D20220503-20220503"
      id="id3VybDovL2RvY3MudjEvZG9jOjY5NzYzMGNhYWRmNTQ4YjFhNmYxNDM0ZmY4MzNiMWM2L3NlYzo2OTc2MzBjYWFkZjU0OGIxYTZmMTQzNGZmODMzYjFjNl8xL2ZyYWc6NzE4NjQ3ODMzOTQ1NDljNTk5NDg4ZDA3MmY2NmJkYmIvdGV4dHJlZ2lvbjo3MTg2NDc4MzM5NDU0OWM1OTk0ODhkMDcyZjY2YmRiYl81OTky_93d9ea11-b403-4c60-9f20-2eda31d53fd9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MH82C5/1N,\\]!   0Q   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R5
MF%USXC84AJ^WOT+#]**=(?$'G]D!9@@A*;,AH8%M=MKIA; %:&)+KB2'\.][
M9,"F4W-,;F++]GEY='3T2DIO*]6;WC!FR$<<"=VO;8Q)OCJ.#C8LIOI:)DS
MFY54,3705&M')XK1, N*(\=WW;834RYJ@U[V;*8&/9F:B LV4T2G<4S5[I9%
M<MNO>;7C@Q>^WAC[P!GT$KIF<V:^)S,%+2=7"7G,A.92$,56_=K0^WKK-VU
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " "AA*-4EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( *&$HU3;7P?M.0$
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *&$HU2?>N\=[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *&$
MHU297)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ H82C5/1N,\\]!   0Q   !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *&$
MHU2?H!OPL0(  .(,   -              "  7\,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ H82C5)>*NQS     $P(   L              ( !6P\
M %]R96QS+RYR96QS4$L! A0#%     @ H82C5-M?!^TY 0  , (   \
M         ( !1!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *&$HU0D
M'INBK0   /@!   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( *&$HU1ED'F2&0$  ,\#   3
M      "  8\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' -D3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mdxg-20220503.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mdxg-20220503.htm">mdxg-20220503.htm</File>
    <File>a20220503ex991q12022earnin.htm</File>
    <File>mdxg-20220503.xsd</File>
    <File>mdxg-20220503_lab.xml</File>
    <File>mdxg-20220503_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mdxg-20220503.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mdxg-20220503.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdxg-20220503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdxg-20220503_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mdxg-20220503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mdxg",
   "nsuri": "http://mimedx.com/20220503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220503.htm",
      "contextRef": "i989923ec8f974009805151eba4d91949_D20220503-20220503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page Document",
     "role": "http://mimedx.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20220503.htm",
      "contextRef": "i989923ec8f974009805151eba4d91949_D20220503-20220503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001376339-22-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001376339-22-000060-xbrl.zip
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M=\,Z'=.:7T-N]KFY.@!N$3Y\LL?P6C^4ZR;9_-8D"=;GO?/3DW^SKN\'B>_
MXL]D&,7L7PD/83(*/2XG(N0QHA'W77C Y[XCN<>N1)1X<?0=UF:E:Z.1WLD8
M'G?F5FLOKK9>A]7.+^Y"Q.R:>[#H8,!^;+3-#CN7G@=D"$L;>,*)(Z"GI.^)
MPQ,YE#%<O15^(EC/1^J*!!L$(8M'@MV,9.BRZSCD1%3I!Z1/=X^#\83[TU\B
M^.4#'!,$Y:<@C <!? P__BD,W,1Y BA7$,BV;H#=0'3C/A\*8E!QP#X$L!L
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MAKE% CL!6$2H;)!R 50-\QWP*#Y$B?X%WXW$&FH+6#^1.*KZ!/$\\BD!%7'
M!E"L +0#N*R$[0A5M=KO#. *VY:XBA@'"4P&6(< 5I=NGN8AZ< !@AFA#],$
MN!*7(0Q*GR!MPYOBM]=2VRBE!+..7II)H/QJ[T+AT8*6'$WIB]I_5)V]POM1
MX"7Q\BO?\$VI_X["=.0)T-=A'[2(+X=\  K .^[=\6GTYN5<8M^=Y;@R(HU=
M*UN ?P/&)Z3IND0K?> Q(#IP6X%J #5!RP+$!YLA6J4*YW##U\BJ232:8QMW
MZ,A$+5#"?L.'O>D"SR!NP(&(X#*L[5:KC#A>JK-%"2B<(=X@G.;L-I N?A<5
M/R58,OT[TPV9TCAW7%)H&P"VPP6!'XZ5SA.0\03D*C@RMT$"&AURHT-\1!L0
M',0#:N<Q&NVP$3G##B&V;!;TT2\-.V2@4+@3GH?_XNLYF31.(B?Q@N@+[%Z<
M$TTF.\UVH#L)I:<]17KZJ><[OH.9BP$N JU:V&5\0:)?"/7Z= 8,I8]26.;]
M=<K+ :JCTFP$L<!O+DPQ-5@7#BJ^@O#0UB#I>)E.H=#61XN6P"A]/[@E9 ?@
MPJ?Z4W8"*O95, +K^0\>C:9\PBHOY IZN!./T.03" I2;8T\.'[^H0[@2@%R
M\#V\5K!C':4 XS8&R%P6H G::\RN8P$[O7W O!(IRP,\/4>+ I[6</T]4TM[
M&:9\#Q ?&!DU@'04P&#)6[YJXGD+PV#11#ADJ7GP3FJJ(6D@G:Q4OS-+19MS
MH+M*4O!1(J JJ>R5LR!P-9!.PF3(NB[PK=F#E;,3T.]2X9.-#Y]RX6F3+:L2
MN\&J9_8W=]V<[7TS O8=A$/@U?]-?:LT4:40(VO7[BI@[-J*<LEZ19Z)1AG:
M\Z'L)W$0DOJ'0A7E7\XT1RXU $L4?]$>PH8P4&J4;1:A6!SCG&$F$RW#M6=$
M*U<1L#[4##APS$P!!I[I#T+02D-@E8GFL$K#!7UB9@R@VRPC GI("2%B_'!)
M>08C 68)V#C*Y!S)B7)0IF8M:,]@J"!S@!G/!!_@H'9^TH>E(#^E4C$\[U#\
MG<C)1 $/U HTC64T4C:FLCU!H\^KS^GGP.CQE"3"L7H,9@)P'A#EHV-U:<]F
M4%"FAM: T'F@C%[/2YV ?>F!_90#BS"TUT1[",FAJG1N'Q"734A'!_U:>TK1
MNZ! L%9_V1U'^-(9"YW\72E?X[JCS _PJ(>/1R3U-[W\"= H?!1LP4'\CI3[
MY8'4)3 ;89[O#JWVY!'GUL^63:L/I@@9FD>O+V>.Y@!FU<Q&'<%Q)5!_0FMS
M[K3'!R,RFC_'':MS7(.Y:$5[Y!4<<9_5?E):O;)DD3_@44(V$O#&B=36J8<*
M+0R8FB/TWK50_N]ZP\I<Y:S"HU311,,FN#LPZ6PYF]/\(; S.P2>Y ^!M3\:
M$1-T:'<V?GH XM)Q"&B94:)<^A$?9X=:'O!-6LSZ0ZQMP<)O>ZNV".>Z<X>.
M^;,*V#(.T!?A(:"(%'>H$I&_0YL1VZ%?_A.D!<H3F&U.6?\>JB/I!JX8@_37
MIT5T+!5$\>'\&4_FCE<'P'B82(XO\AJB^Q(><' 5"&B2^4!*0';H7OJ*C@24
MAJ[D?1&3PS>(6>(YY&+V \7\YPX.0G1*I<=:8_X7< 4^GB3Y$YU1@(P!P)C$
M(&R5D-X3VD8)#0TA4KU6H03Y&E%-T8C!8T*>Z^D8-<IDC%;(JE/ERG7W\_$!
MNYZ00^=<"-Q^9=B#R6 ?7>'6XZUC^&;$/H\DJ,,T$^4;^DA*G+(N/LIQ7QU
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ML R-S_CFK X5A0^OR=XM\59KCC8"DL'\Z4DHQYBC1]4FU(ZGNZBBJ"O6P:K
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M&\D'[ 5LMXX^10=9#_&YU*I** 8B3*O6JMRK67;5:0X>)QD\#M8G]*W"^5U
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MS(LL(D4*2X24MP_)_I=Q9C#,E>52EN'JLERKRAO-2@8I)-?BU\[7GH.)JSD
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MA50QO9.1,-:9:=]DEBNXHV:&8THE(Y6;3E!1<TXFJ%W&ZS#1S(N4W!)!M8I
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M^L,Z.E@%9)-]%J $>5+<"A:/> S_P9F*".1)MFMP+1(P31XEV 13+P0F/)[
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M^(+]Z5M_[TRH,ZR'?S;X#5!+ P04    " "AA*-4SPS*FV *  #37@  %0
M &UD>&<M,C R,C U,#-?;&%B+GAM;-6<;W.;.A;&W_=3L+YO=F>N:H0$0ITV
M=[JY[9W.YK:=)IW>V9T=C_XF3#%D,&F2;[\"VXFQP19@4_9-0FQQ])P'_XZ0
MD//ZMX=Y[/Q0V2)*DS<3^-*=."H1J8R2ZS>3KU?O03CY[>S%B]=_ ^"O?WZY
M<'Y/Q=U<);ESGBF6*^G<1_F-\TVJQ7='9^G<^99FWZ,?#("S\J3S]/8QBZYO
M<L=S/6_[W>R5RRG44%*  TC,#\I R!@%*'0%YEY ,"2_7K\BE&NJ,03,]1G
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MJ3)SGUDCN/(A>I?D4?[X5DIS31>?4W/_%/\[NCU/I9HI$KJ!""3@-!  &_0
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MP?H&3>AM>GMACLY>K%^)EO\%_>S%_P!02P,$%     @ H82C5':P8*FT!@
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M(X<\,#J,@0EW,%\NX6BQ?[-X(MX9#ASMW7_1O70/[!_M_0]02P$"% ,4
M" "AA*-4L(ETP&DS   )#@( '@              @ $     83(P,C(P-3 S
M97@Y.3%Q,3(P,C)E87)N:6XN:'1M4$L! A0#%     @ H82C5+4E,!1@&0
MVY(  !$              ( !I3,  &UD>&<M,C R,C U,#,N:'1M4$L! A0#
M%     @ H82C5'Z'CH%[ @  C@<  !$              ( !-$T  &UD>&<M
M,C R,C U,#,N>'-D4$L! A0#%     @ H82C5,\,RIM@"@  TUX  !4
M         ( !WD\  &UD>&<M,C R,C U,#-?;&%B+GAM;%!+ 0(4 Q0    (
M *&$HU1VL&"IM 8  'XQ   5              "  7%:  !M9'AG+3(P,C(P
A-3 S7W!R92YX;6Q02P4&      4 !0!0 0  6&$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
